Table 3 Treatment of psychiatric patients with depressive disorders during an eight-week follow-up (n = 107)
|  | All patients n = 107  N (%)a | TRD n = 20b N (%) | non-TRD n = 87  N (%) | p-value* |
|---|---|---|---|---|
Follow-up appointments | ||||
 - Psychiatrist (A) | 73 (68.2) | 13 (65) | 60 (69) | 0.963c |
 - Other health care worker (B) | 74 (69.2) | 13 (65) | 61 (70.1) | 0.884c |
 - Any appointment overall (A, B, or A + B) | 94 (87.9) | 17 (85) | 77 (88.5) | 1d |
 - No follow-up appointments | 12 (11.2) | 2 (10) | 10 (11.5) |  |
Psychotherapy and other treatment sessions | ||||
 - Psychotherapy | 14 (13.1) | 4 (20) | 10 (11.5) |  |
 - Supportive meetings at another service provider | 64 (59.8) | 14 (70) | 50 (57.5) |  |
 - Family meetings | 1 (0.9) | 0 | 1 (1.1) |  |
 - Group counselling | 5 (4.7) | 0 | 5 (5.7) |  |
 - Visits at occupational health care unit | 2 (1.9) | 1 (5) | 1 (1.1) |  |
Use of antidepressants (ADs) at eight weeks | ||||
Patients using ADs (ntot for AD use): | 97 (90.7) | 18 (90) | 79 (90.8) | 1d |
 - using AD monotherapy only | 67 (69.1) | 14 (77.8) | 53 (67.1) |  |
 - using a combination of ADs | 30 (30.9) | 4 (22.2) | 26 (32.9) | 0.439c |
 - AD dosage compatible with Finnish DCG recommendations for a therapeutic dose | 91 (93.8) | 18 (100) | 73 (92.4) | 0.298d |
Did the patient continue using the index AD prescribed at BL until eight weeks? | ||||
 - Yes, used index AD as only AD | 50 (51.5) | 10 (55.6) | 40 (50.6) |  |
 - Yes, used index AD in combination with other AD(s) | 27 (25.2) | 3 (16.7) | 24 (30.4) |  |
 - No, index AD switched to another AD, which was used alone or combined with other AD(s) | 15 (15.5) | 4 (22.2) | 11 (13.2) |  |
 - No, index AD terminated, patient continued using previously prescribed AD(s) | 5 (4.7) | 1 (5.6) | 4 (5.1) |  |
 - No, all ADs terminated | 8 (7.5) | 1 (5.6) | 7 (8.9) |  |
 - No, never started using the index AD and not using any other AD | 1 (0.9) | 0 | 1 (1.3) |  |
Augmentation pharmacotherapy (combined with ADs) | Â | 1d | ||
 - Atypical antipsychotic (AA) (quetiapine, minimum 50 mg/day) | 9 (9.3) | 1 (5.6) | 8 (10.1) | 1d |
 - Mood stabilizer (lamotrigine) | 1 (1.0) | 0 | 1 (1.3) |  |
Monotherapy: using one AD or one AA only (quetiapine ≥ 50 mg/day) | 62 (58.0) |  | ||
ECT during follow-up (n = 107) | 1 (0.9) | 0 | 1 (1.5) |  |
New hospitalization during follow-up (n = 107) | 2 (1.9) | 0 | 2 (2.3) |  |